Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

MeSH terms

• Adult
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Brentuximab Vedotin / administration & dosage
• Brentuximab Vedotin / adverse effects
• Cisplatin / administration & dosage
• Cisplatin / adverse effects
• Cytarabine / administration & dosage
• Cytarabine / adverse effects
• Dexamethasone / administration & dosage
• Dexamethasone / adverse effects
• Disease-Free Survival
• Female
• Hodgkin Disease / drug therapy*
• Hodgkin Disease / mortality*
• Hodgkin Disease / pathology
• Humans
• Male
• Middle Aged
• Recurrence
• Salvage Therapy*
• Survival Rate